UC WAR. PUT 03/25 QIA/ DE000HD402Q3 /
| 6/21/2024 9:42:12 PM | Chg.+0.0100 | Bid9:59:00 PM | Ask9:59:00 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.4100EUR | +2.50% | - Bid Size: 10,000 |
- Ask Size: 10,000 |
QIAGEN NV | 40.00 - | 3/19/2025 | Put |
GlobeNewswire
6/13
QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput N...
GlobeNewswire
6/12
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to su...
GlobeNewswire
6/11
QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious dis...
GlobeNewswire
6/6
QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition per...
GlobeNewswire
6/5
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of it...
GlobeNewswire
6/3
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improv...
GlobeNewswire
5/30
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global...
GlobeNewswire
5/30
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global...
GlobeNewswire
5/29
QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision ...
GlobeNewswire
5/14
QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical devic...
GlobeNewswire
5/13
QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accura...
GlobeNewswire
5/7
QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics
GlobeNewswire
5/7
Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
GlobeNewswire
5/7
Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
GlobeNewswire
5/2
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inher...
GlobeNewswire
4/29
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
GlobeNewswire
4/25
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ...
GlobeNewswire
4/24
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and comba...
GlobeNewswire
4/18
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing...
GlobeNewswire
4/3
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Ann...
